Format

Send to

Choose Destination
Breast Care (Basel). 2012 Oct;7(5):414-6. doi: 10.1159/000343614.

Advanced breast angiosarcoma completely responding to gemcitabine-containing chemotherapy.

Author information

1
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Abstract

in English, German

BACKGROUND:

For patients with anthracycline-resistant metastatic angiosarcoma, there is currently no available standard for second-line therapy, and a need exists for novel effective regimens to improve response rates.

CASE REPORT:

We report here on a case of a primary angiosarcoma of both breasts in a 34-year-old woman presenting with lung metastases. Upon completion of 3 cycles of the MAID regimen (mesna, adriamycin, ifosfamide, dacarbazine), computed tomography showed disease progression. Subsequently, a second-line chemotherapy was started using the GVP regimen (gemcitabine, vincristine, cisplatin). Complete response of the lung metastases was achieved after 6 cycles of treatment.

CONCLUSION:

In the absence of an effective therapy among patients with anthracycline-resistant metastatic breast angiosarcoma, a GVP chemotherapy regimen can be performed as a selective option.

KEYWORDS:

Angiosarcoma; Breast neoplasm; Chemotherapy; Cisplatin; Gemcitabine; Lung metastases; Vincristine

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center